CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced / Metastatic Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 540 (planned)
- Started
- Feb 17, 2026
- Main results expected
- Feb 2029
- Fully finished
- Feb 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicities
Measured over: From the first dose of study drug up until approximately 1 month
Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicable
Measured over: From the first dose of study drug up until approximately 1 month
All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to dose modifications
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to treatment discontinuation
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measured over: From the first dose of study drug until 90 days after the last dose of study drug
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07335497 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC